Trial results comparing semaglutide to DPP4 inhibitors for the risk of dementia onset in patients with diabetes were posted on ClinicalTrials.gov on 2025-11-10. The study, titled "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)," found that patients treated with semaglutide consistently showed lower incidence rates of dementia onset compared to those treated with DPP4 inhibitors, with one measurement showing 4.40 incidence rate per 1000 person-years for semaglutide versus 6.06 for DPP4 inhibitors.
Background
This study investigated the comparative risk of dementia/Alzheimer's disease onset among patients with diabetes. It specifically compared medications targeting certain metabolic pathways, such as semaglutide, against alternative treatments for diabetes, like DPP4 inhibitors.
Trial design
The completed study (NCT05768945), titled "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors," enrolled a large cohort of 742,670 participants. The trial aimed to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients with diabetes treated with semaglutide and those treated with DPP4 inhibitors.
Key results
The study measured the 'Time to Dementia Onset' across several analyses, reporting incidence rates per 1000 person-years for both treatment groups:
- For one analysis, semaglutide showed an incidence rate of 4.40 per 1000 person-years, compared to DPP4 inhibitors at 6.06 per 1000 person-years.
- Another measurement reported semaglutide at 4.69 per 1000 person-years, versus DPP4 inhibitors at 6.71 per 1000 person-years.
- A third analysis indicated an incidence rate of 2.80 per 1000 person-years for semaglutide, while DPP4 inhibitors had an incidence rate of 10.24 per 1000 person-years.
- Finally, a separate measurement showed semaglutide at 0.37 per 1000 person-years, compared to DPP4 inhibitors at 0.61 per 1000 person-years.
What this means
The consistent observation of lower incidence rates for dementia onset in patients treated with semaglutide across multiple measurements suggests a potential association between semaglutide use and a reduced risk of developing dementia/Alzheimer's disease in patients with diabetes, compared to treatment with DPP4 inhibitors. These findings may have implications for treatment selection in diabetes patients, particularly those with concerns regarding cognitive decline.
Source
The information for these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT05768945, titled "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors," were posted on 2025-11-10 on clinicaltrials.gov.